Received Nov 26, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | P2443 | — |
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
third dose was administered before the 5 month period; received 2nd dose late; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 61-year-old patient who received HAB (Twinrix) (batch number P2443, expiry date 18-SEP-2027) for prophylaxis. Co-suspect products included HAB (Twinrix) for prophylaxis. Previously administered products included Twinrix (received 1st dose on 26-FEB-2025). On 08-SEP-2025, the patient received the 3rd dose of Twinrix. On 17-JUL-2025, the patient received the 2nd dose of Twinrix. On 17-JUL-2025, not applicable after receiving Twinrix and an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: received 2nd dose late). On 08-SEP-2025, the patient experienced drug dose administration interval too short (Verbatim: third dose was administered before the 5 month period). The outcome of the drug dose administration interval too long and drug dose administration interval too short were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 20-NOV-2025 The vaccine administration facility was the same as primary reporter. The batch number was not provided upon follow up with the reporter. This case is linked with US2025150964 and US2025150969, reported by same reporter.; Sender's Comments: US-GSK-US2025150964:Same Reporter US-GSK-US2025150969:Same Reporter